April 2016 in “Journal of The American Academy of Dermatology” Finasteride and SSRIs together increase impotence and low libido risk in men.
24 citations
,
September 2005 in “Journal of Cellular Biochemistry” Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.
January 2005 in “Yaowu fenxi zazhi” Domestic and imported finasteride tablets are bioequivalent.
3 citations
,
January 2008 in “Drug Safety” January 2004 in “Europe PMC (PubMed Central)” Finasteride sustained-release tablets are stable.
21 citations
,
August 1994 in “Clinical endocrinology” 5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
12 citations
,
May 2015 in “Molecular Medicine Reports” Troxerutin helps protect skin cells from oxidative stress and may be good for treating hair loss.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Cilostazol may help hair grow and could be a new treatment for hair loss.
March 2023 in “The Journal of Urology” Men with better urinary symptoms have a lower risk of death.
April 2023 in “Journal of Investigative Dermatology” Acne patients have higher skin mTORC1 activity, which is reduced by isotretinoin treatment.
January 2009 in “Chinese Journal of Drug Application and Monitoring” Finasteride granules and tablets work the same in the body.
June 2021 in “Psychiatria Danubina” The antidepressant escitalopram likely caused hair loss in a patient.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
4 citations
,
December 2024 in “International Journal of Nanomedicine” Resveratrol-loaded nanovesicles effectively promote hair growth and treat hair loss.
4 citations
,
July 2022 in “Clinical Cosmetic and Investigational Dermatology” Clascoterone 1% cream is a promising new treatment for acne.
54 citations
,
May 2015 in “Endocrinology” Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.
Urtica laetevirens extract significantly reduces 5α-reductase activity.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
2 citations
,
July 2019 in “Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)” No proven link between isotretinoin and depression.
May 2019 in “Gastroenterology” Androgen lowering medications don't significantly change HCV-related liver cancer risk in men.
31 citations
,
January 1981 in “Pharmacology & Therapeutics” Oral retinoids are effective for treating severe skin disorders but have reversible side effects and risks for pregnant women.
13 citations
,
August 1997 in “Steroids” Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.
August 2025 in “Ciencia Latina Revista Científica Multidisciplinar” Rosemary shows potential for treating various health issues.
8 citations
,
October 2021 in “The international journal of risk and safety in medicine” The document sets criteria for diagnosing long-term sexual dysfunctions caused by certain medications.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
3 citations
,
September 2019 in “PLOS ONE” Genetic variations affect dutasteride treatment response for male pattern hair loss.
4 citations
,
July 2020 in “Research Square (Research Square)” The research helps understand how finasteride works and aids drug development.
31 citations
,
February 1982 in “Archives of dermatology” Etretinate was effective for certain skin conditions, but caused side effects like chapped lips, dry mucous membranes, and hair loss.
June 2026 in “The Journal of Sexual Medicine” The study analyzed the FDA Adverse Event Reporting System (FAERS) database to investigate psychiatric adverse drug reactions (ADRs) associated with 5-alpha reductase inhibitors (5-ARIs), specifically finasteride and dutasteride. A total of 27,578 ADRs were reported for finasteride, with 29.3% being psychiatric, while dutasteride had 9,161 ADRs with 13.3% psychiatric. Finasteride showed a higher disproportional reporting of psychiatric ADRs compared to dutasteride, with common issues including depressive disorders, anxiety, suicidality, and libido disorders. Despite the findings, a causal relationship between these psychiatric issues and 5-ARIs cannot be conclusively determined, highlighting the need for ongoing surveillance and further studies to clarify their neuropsychiatric safety profile.